Protagenic Therapeutics (PTIX) - Total Liabilities
Based on the latest financial reports, Protagenic Therapeutics (PTIX) has total liabilities worth $6.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Protagenic Therapeutics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Protagenic Therapeutics - Total Liabilities Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Protagenic Therapeutics asset portfolio.
Protagenic Therapeutics Competitors by Total Liabilities
The table below lists competitors of Protagenic Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reneuco Berhad
KLSE:7130
|
Malaysia | RM469.23 Million |
|
Cho Thavee Public Company Limited
BK:CHO
|
Thailand | ฿2.53 Billion |
|
Distribution Finance Capital Holdings PLC
LSE:DFCH
|
UK | GBX872.21 Million |
|
Grupo Vasconia S.A.B
MX:VASCONI
|
Mexico | MX$2.18 Billion |
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
UK | GBX824.00K |
|
CardioComm Solutions Inc.
V:EKG
|
Canada | CA$823.97K |
|
Sky Gold Corp
V:SKYG
|
Canada | CA$385.92K |
|
Ausmon Resources Ltd
AU:AOA
|
Australia | AU$1.56 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Protagenic Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Protagenic Therapeutics (PTIX) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagenic Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagenic Therapeutics (1995–2025)
The table below shows the annual total liabilities of Protagenic Therapeutics from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.82 Million | +623.81% |
| 2024-12-31 | $942.76K | +43.88% |
| 2023-12-31 | $655.25K | -41.49% |
| 2022-12-31 | $1.12 Million | +0.17% |
| 2021-12-31 | $1.12 Million | -44.90% |
| 2020-12-31 | $2.03 Million | +37.41% |
| 2019-12-31 | $1.48 Million | +62.67% |
| 2018-12-31 | $907.77K | +61.61% |
| 2017-12-31 | $561.69K | -17.98% |
| 2016-12-31 | $684.86K | -2.72% |
| 2015-12-31 | $704.00K | +11.75% |
| 2015-06-30 | $630.00K | +99.37% |
| 2014-12-31 | $316.00K | 0.00% |
| 2013-12-31 | $316.00K | -98.26% |
| 2012-12-31 | $18.18 Million | +62.76% |
| 2010-12-31 | $11.17 Million | -41.98% |
| 2009-12-31 | $19.25 Million | -20.17% |
| 2008-12-31 | $24.11 Million | +239.73% |
| 2007-12-31 | $7.10 Million | +66.19% |
| 2006-12-31 | $4.27 Million | +4421.01% |
| 2005-12-31 | $94.47K | -97.76% |
| 2004-12-31 | $4.21 Million | -51.88% |
| 2003-12-31 | $8.76 Million | +1.21% |
| 2002-12-31 | $8.65 Million | -10.83% |
| 2001-12-31 | $9.71 Million | +7.12% |
| 2000-12-31 | $9.06 Million | -6.18% |
| 1999-12-31 | $9.66 Million | +28.28% |
| 1998-12-31 | $7.53 Million | +204.82% |
| 1997-12-31 | $2.47 Million | -55.33% |
| 1996-12-31 | $5.53 Million | +54.90% |
| 1995-12-31 | $3.57 Million | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.